SecondWave Systems has made a breakthrough in the treatment of rheumatoid arthritis (RA) with their novel ultrasonic stimulation technology. The pilot clinical study involved the noninvasive treatment of 13 participants, significantly improving disease activity.
The wearable MINI™ device delivers ultrasound stimulation to the spleen, effectively reducing inflammation and symptoms. Ten out of 13 participants experienced benefits during the 8-week study period, with positive feedback regarding the treatment experience.
Rheumatologist Dr. Erik Peterson, the principal investigator, emphasized the promising results in that more than two-thirds of the participants showed significant clinical improvement, and the intervention was well-tolerated and safe.
Dr. Hubert Lim, Chief Scientific Officer at SecondWave Systems, highlighted the potential of splenic ultrasound therapy by indicating that this study demonstrates that ultrasound can directly modulate disease symptoms and inflammation in patients with rheumatoid arthritis.
SecondWave Systems is currently developing a randomized controlled trial for at-home treatment of RA using the MINI technology platform. This advancement aims to provide patients with a noninvasive and personalized treatment option for a debilitating condition.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.
